![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2006, American Society for Microbiology Two-Step Regulation of Ad4BP/SF-1 Gene Transcription during Fetal Adrenal Development: Initiation by a Hox-Pbx1-Prep1 Complex and Maintenance via Autoregulation by Ad4BP/SF-1 Division for Sex Differentiation, National Institute for Basic Biology, Myodaiji-cho, Okazaki 444-8787, Japan,1 Laboratory of Molecular and Cellular Biology, Department of Life Science, Faculty of Bioresources, Mie University, Tsu 514-8507, Japan2 *Corresponding author. Mailing address: Division of Sex Differentiation, National Institute for Basic Biology, Myodaiji-cho, Okazaki 444-8787, Japan. Phone: 81-564-59-5865. Fax: 81-564-59-5866. E-mail: moro/at/nibb.ac.jp. Received February 7, 2006; Revised March 12, 2006; Accepted March 22, 2006. This article has been cited by other articles in PMC.Abstract The orphan nuclear receptor Ad4BP/SF-1 (adrenal 4 binding protein/steroidogenic factor 1) is essential for the proper development and function of reproductive and steroidogenic tissues. Although the expression of Ad4BP/SF-1 is specific for those tissues, the mechanisms underlying this tissue-specific expression remain unknown. In this study, we used transgenic mouse assays to examine the regulation of the tissue-specific expression of Ad4BP/SF-1. An investigation of the entire Ad4BP/SF-1 gene locus revealed a fetal adrenal enhancer (FAdE) in intron 4 containing highly conserved binding sites for Pbx-Prep, Pbx-Hox, and Ad4BP/SF-1. Transgenic assays revealed that the Ad4 sites, together with Ad4BP/SF-1, develop an autoregulatory loop and thereby maintain transcription, while the Pbx/Prep and Pbx/Hox sites initiate transcription prior to the establishment of the autoregulatory loop. Indeed, a limited number of Hox family members were found to be expressed in the adrenal primordia. Whether a true fetal-type adrenal cortex is present in mice remained controversial, and this argument was complicated by the postnatal development of the so-called X zone. Using transgenic mice with lacZ driven by the FAdE, we clearly identified a fetal adrenal cortex in mice, and the X zone is the fetal adrenal cells accumulated at the juxtamedullary region after birth. The adrenal 4 binding protein/steroidogenic factor 1 (Ad4BP/SF-1) (NR5A1) (42) is an essential transcription factor required for reproduction and endocrine organogenesis (39, 44, 57). Adrenal glands and gonads do not develop in mice with a targeted disruption of the Ad4BP/SF-1 gene (32, 49). Additionally, the ventromedial hypothalamus (VMH), pituitary gonadotrope, and spleen developed abnormally in the mice (22, 38, 54). Moreover, the Ad4BP/SF-1 gene dosage appears critical for adrenal development; heterozygous mouse embryos developed hypoplastic adrenal glands (7) and displayed aberrant early gonadal development (43). Humans appear more sensitive to reduced Ad4BP/SF-1 expression because individuals with a single mutated copy of this gene exhibit defective adrenal and/or gonadal development and function (2, 5, 11, 15). Because the gene dosage dramatically affects the target tissues, it is essential for the body to tightly control levels of Ad4BP/SF-1 gene expression. Several factors regulating the expression of the Ad4BP/SF-1 gene have been identified. An E-box binding site within the basal promoter is critical for Ad4BP/SF-1 expression (41). Using reporter gene assays, Pod1/capsulin was indicated to suppress Ad4BP/SF-1 gene transcription through binding to the E box (56). The disruption of the Pod1/capsulin gene confirmed the suppressive function of the E box (12). A study using transgenic (Tg) mice harboring the 5′ upstream region of Ad4BP/SF-1 indicated a role for Wt1 in controlling the gene expression (59), and Sox9 is also required for Ad4BP/SF-1 gene expression in cultured cells (52). Finally, gene disruption of Lhx9 (6) clearly indicated that this transcription factor lies upstream of Ad4BP/SF-1. Although these factors are assumed to regulate Ad4BP/SF-1 gene transcription, studies of the factors all focused on the basal promoter region but not the upstream or downstream regulatory region. Recently, Shima et al. (53) demonstrated for the first time that a distal enhancer in intron 6 that is conserved among animal species is important for VMH-specific Ad4BP/SF-1 gene transcription. However, the regulatory regions for the other tissues remained elusive. PBX1 and its Drosophila equivalent, EXD, are three-amino-acid loop extension (TALE) class homeodomain proteins that heterodimerize with other members of the TALE homeodomain subfamily, PREP, MEIS, and HTH (8). Heterodimerization modifies both transcriptional activity and subcellular localization (1, 34, 45, 47). Additionally, PBX interacts with HOX to activate gene transcription. Interestingly, the transcriptional activity of the PBX-HOX complex is enhanced through interactions with PREP or MEIS (13, 23, 46, 50). Targeting studies demonstrated a critical role for Pbx1 as a developmental regulator for multiple tissues. Notably, the gonads of Pbx1-deficient mice exhibited only rudimentary sexual differentiation and decreased cell proliferations, while the adrenal glands did not develop at all. Consistent with other data, Ad4BP/SF-1 expression in the adrenal primordium was virtually undetectable in the mice, suggesting that Pbx1 is an essential upstream regulator of Ad4BP/SF-1 during adrenal development (51). The adult adrenal gland consists of two functionally distinct cell layers, the outer cortex and inner medulla. Cortex development and differentiation gradually occur after birth, and the fetal cortex is comprised of cells that are fundamentally different from those of the adult cortex. During the transition from fetal cortex to adult cortex, the fetal cortex undergoes extensive regression, while cells of the adult cortex proliferate to occupy the entire cortical region. Although this transition has been confirmed in various mammalian species, in mice it has been controversial (27). Given the essential role of Ad4BP/SF-1 in adrenal development, we attempted to determine the distal regulatory sequences governing adrenal-specific gene expression by using Tg mouse assays. Successfully, an enhancer was identified in intron 4 that drives Ad4BP/SF-1 gene transcription in a fetal adrenal-specific manner by two successive steps, initiation and maintenance, which are achieved through the Hox-Pbx1-Prep1 complex and Ad4BP/SF-1, respectively. Moreover, we used Tg mice expressing lacZ driven by this enhancer to demonstrate a link between the fetal adrenal cortex and the X zone in the mouse adrenal gland. MATERIALS AND METHODS DNA construction for Tg assay and FISH analysis. The mouse Ad4BP/SF-1 gene has multiple noncoding first exons, Ia, Ig, and Ix (28), and the first methionine is located 11 bp upstream of the SplI site in the second exon. A 5.8-kb KpnI-SplI DNA fragment which is comprised of the 1.9-kb upstream region, exon 1, intron 1 (containing exons Ig and Ix), and the region of exon 2 upstream of the SplI site, was used as a basal promoter. β-Galactosidase (lacZ), together with the simian virus 40 poly(A) signal, was inserted into the SplI site to generate the Ad4BP-lacZ cassette. The Ad4BP-lacZ cassette was introduced into the NotI site of the SuperCos-1 cosmid vector (Stratagene) to produce cAd4BP-lacZ (Fig. (Fig.1A).1A
The generation of Tg mice and lacZ staining. Tg mice were generated as described previously (19). The cosmid and plasmid DNAs were digested with NotI and NotI/SalI, respectively, and the linear DNA fragments were used for microinjection. The founder animals were subjected to PCR with primers for lacZ and enhanced green fluorescent protein (EGFP). The primers for lacZ were GCCGAAATCCCGAATCTCTATC and GATTCATTCCCCAGCGACCAG, while those for EGFP were GAGCTGGACGGCGACGTAAAC and CACCTTGATGCCGTTCTTCTGC. LacZ activities of the fetuses were examined as described previously (19). Animals were maintained and cared for in accordance with the guide by the Institutional Animal Care and Use Committee of the National Institute for Basic Biology. All experimental protocols were approved by the committee. Immunohistochemistry. Samples were fixed overnight in phosphate-buffered saline (PBS) containing 4% paraformaldehyde (PFA) at 4°C and embedded in paraffin. Five-micrometer sections were incubated with rabbit anti-Ad4BP antiserum (1/2,000) (37). After being washed three times with PBS containing 0.1% Triton X-100 for 10 min, the sections were incubated with Cy3-anti-rabbit immunoglobulin G secondary antibody (1/250; Jackson ImmunoResearch) for 1 h, washed three times with PBS containing 0.1% Triton X-100 for 10 min, and then incubated with the anti-β-galactosidase (1/1,500) antibody. Alexa-anti-rabbit immunoglobulin G (1/250; Molecular Probes) was used as the second antibody, and samples were washed three times with PBS containing 0.1% Triton X-100 for 10 min. Electrophoretic mobility shift assays. Double-stranded oligonucleotides containing 5′ protruding ends were labeled with 32P-dCTP and Klenow polymerase. The nucleotide sequences for the sense strands of the probes were GCCTGTTGGCCTTGGCTGCC for Ad4-site 1, GCCTGTTGGaaTTGGCTGCC for mAd4-site 1, GCTGTGTCAAGGCTCCAAGAT for Ad4-site 2, GCTGTGTCAAttCTCCAAGAT for mAd4-site, GACTGCAAATGACCTTGTTCC for Ad4-site 3, GACTGCAAATGAaaTTGTTCC for mAd4-site 3, GTTCCCAAGGTGGCAAGAGG; for Ad4-site 4, GTTCCCAAttTGGCAAGAGG; for mAd4-site 4, AGTGCGTCTGTCAGTACTGGGCTGATAAATAATTGCTCAGCC for PP/PH, AGTGCGTCTcgagGTACTGGGCTccTAccccATTGCTCAGCC for mPP/mPH, AGTGCGTCTGTCAGTACTGGGCTccTAccccATTGCTCAGCC for PP/mPH, AGTGCGTCTcgagGTACTGGGCTGATAAATAATTGCTCAGCC for mPP/PH, AGTGCGTCTGTCAGTACTGGG for PP, AGTGCGTCTcgagGTACTGGG for mPP, GTACTGGGCTGATAAATAATTGCTCAGCC for PH, and GTACTGGGCTccTAccccATTGCTCAGCC for mPH. Lowercase letters in the nucleotide sequences indicate mutation sites. All proteins, Ad4BP/SF-1, Pbx1a, Pbx1b, and Prep1 were prepared using a coupled TNT transcription and translation kit (Promega). Pbx1 and Prep1 were translated simultaneously to facilitate complex formation. Two-microliter reticulocyte lysates containing Pbx1/Prep1 with or without 2-μl reticulocyte lysates containing Hox proteins were incubated with 32P-labeled oligonucleotide probe in 15 μl binding buffer as described previously (3). After 30 min of incubation on ice and 60 min thereafter at room temperature, DNA-protein complexes were separated (36). cDNA cloning for Pbx1, Prep1, and Hox expressed in fetal adrenal glands. cDNAs for Pbx1a, Pbx1b, Prep1, and Hox were cloned by reverse transcription- PCR (RT-PCR). The primers used were as follows: P1-PBX1a/S (354)-BamHI (gttcggatccGAGCCTTCAGAGATGGACGAG) and P2-PBX1a/AS(1737)-HindIII (gccccaagcttGCTTCGACCTCCAGTCTGAC) for Pbx1a, P1-PBX1a/S (354)-BamHI (gttcggatccGAGCCTTCAGAGATGGACGAG) and P3-PBX1b/AS(1633)-HindIII (gccccaagcttCCTGCGGACTGTACATCTGAC) for Pbx1b, P1-Prep1/(57)S-SplI (ccgtacgTCTCACTAACCATGATGGCG) and P2-Prep1/(1412)AS (GCAAACAGTGAAGAGTCCAGC) for Prep1, mHoxA2/S(178)EcoRI (cctagaattcGGAGAAGGCCATGAATTACGA) and mHoxA2/AS(1344)Xba (gccgtctagaCAAAGCCACCTGGTCAAAGGC) for HoxA2, mHoxA7/S(1066)Hind (ctgcaagcttGGGGTTTGGTGTAAATCTGGG) and mHoxA7/AS(1878)XbaI (gccgtctagaTTTCCAACTGTCCTGTGCAGC) for HoxA7, mHoxA9/S(995)EcoRI (cctacgaattCTGCGCGATCCCTTTGCATA) and mHoxA9/AS(2065)XbaI (gccgtctagaGGCTCACTCGTCTTTTGCTCG) for HoxA9, mHoxB5/S(88)Kpn (ggtaggtaccTCCAAAATCACCCAAATGAGC) and mHoxB5/AS(899)XbaI (gccgtctagaGATGGGCTCAAGGTTGGAAGG) for HoxB5, mHoxB9/S(12)Hind (ccgcaagcttAGCGCGCGGATAATGTCTGAG) and mHoxB9/AS(906)XbaI (gccgtctagaGACAGGCTCCAGGTGCAGATG) for HoxB9, mHoxC5/S(68)Hind (ccgcaagctTCCCCGCCATGAGCTCCTACG) and mHoxC5/AS(857)ApaI (tatagggcccATGCGCTTTTGTCTGGGAGGC) for HoxC5, mHoxC6/S(107)Hind (ccgcaagcttCGACCAGGTAAAGGCAAAGGG) and mHoxC6/AS(880)XbaI (gccgtctagaAGTGTGTGATTCGGGGAGCTG) for HoxC6, and mHoxC8/S(220)EcoRI (cctacgaattCGCGGGTTTTCATGTACCCAG) and mHoxC8/AS(1001)XbaI (gccgtctagaAACTTCAAGGGAGTTGCTGGG) for HoxC8. The nucleotides indicated by lowercase letters were artificially added for cloning. cDNAs encoding Pbx1a, Pbx1b, and Prep1 were cloned into pCMX (provided by Kazuhiko Umesono), while cDNAs coding for Hox were cloned into pcDNA3.1 (Invitrogen) to construct expression plasmids. RNA preparation from fetal adrenal glands and RT-PCR. Tg mice carrying FAdE-hsp68-EGFP were used to isolate adrenal primordial cells. The EGFP-labeled cells in the Tg fetuses at embryonic day 10.0 (E10.0) were dissected and incubated in 100 μl PBS containing 0.1% trypsin, 0.1% bovine serum albumin, and 0.75 mM EDTA for 15 min at 37°C. After the addition of 100 μl PBS containing 20% calf serum, the EGFP-labeled cells were collected. Total RNA prepared from the cells was used for cDNA synthesis. A region corresponding to the first to third alpha-helices in the homeodomain was amplified using the degenerate PCR primers, Hox/S (cgcatggatcCARNYSNTRGARYTRGARAARGART) and Hox/AS (acggatctcgagTTCAYBCKNCGRTTYTGRAACCA) (R, A/G; Y, C/T; S, C/G; N, A/C/G/T; B, T/C/G; K, T/G). The amplified fragments were subcloned between the BamHI and XhoI sites of pBluescript and subjected to sequencing analysis. The Hox gene expression was also examined with RNA prepared from the adrenal glands of E13.5 fetuses. RT-PCRs for Pbx1 and Prep1 were performed with total RNA prepared from adrenal primordial cells at E10.5. The PCR primers for Pbx1 were GAGCCTTCAGAGATGGACGAG and GAACTTGCGGTGGATGATGCTC, while those for Prep1 were CAGCACATAGGGCATCCCTA and CAAACAGTGAAGAGTCCAGC. RESULTS Localization of tissue-specific enhancers in the Ad4BP/SF-1 gene locus. The Ad4BP/SF-1 gene has multiple noncoding first exons (Ia, Ig, and Ix), and exon usage is differentially regulated among tissues (28). Therefore, we examined the transcriptional activity of a 5.8-kb DNA fragment upstream of exon 2. This 5.8-kb fragment was ligated to lacZ to produce the Ad4BP-lacZ cassette, and we generated Tg mice with this construct (Fig. (Fig.1A).1A We expected the Ad4BP/SF-1 tissue-specific enhancers to lie within the gene locus, and consequently we used YAC (approximately 400 kb long) and BAC (approximately 200 kb long) clones containing this locus as starting materials. YAC clones frequently recombine unexpectedly. Therefore, we examined whether the YAC clone carried a single chromosomal locus by FISH analysis. As shown in Fig. 1D, a In general, functional genomic regions are conserved among animal species (58). Therefore, the mouse SB7.5 DNA fragment was compared with the corresponding region of the human gene. As shown in Fig. Fig.1H,1H Fetal adrenal enhancer. To characterize the activity of the adrenal-specific enhancer, we generated three Tg mouse lines each with SacK0.6 and SH4.5. LacZ expression patterns in the adrenal glands were similar in all Tg lines at both E11.5 and postnatal day 12 (P9) (data not shown). Thus, we chose one of them (SacK0.6 line 9) to study the transgene expression pattern during adrenal development. As shown in Fig. Fig.2A,2A
The adreno-gonad primordium subsequently divides into two primordia, the adrenal primordium and gonadal primordium. The lacZ activity unexpectedly became weak at E17.5 (Fig. (Fig.2C).2C Function of Ad4 sites in FAdE. In order to identify the sequences that are responsible for FAdE function, we compared the nucleotide sequences of the enhancer regions between mouse and human. Among the sequences conserved between the two animals (Fig. (Fig.3A),3A
Ad4BP/SF-1 activates gene expression by binding to recognition sites. The presence of multiple Ad4 sites in FAdE suggested that Ad4BP/SF-1 has a role in the transcriptional regulation of gene expression in the fetal adrenal gland. To examine this hypothesis, we generated Tg mice harboring a construct carrying mutations in all Ad4 binding sites (Ad4-1234-mut). When we examined Tg mouse fetuses at E11.5, lacZ expression in the Ad4-1234-mut was similar to that in the wild-type construct (Fig. 4A and B
Taken together, these results strongly suggest that Ad4BP/SF-1 binding to the Ad4 sites in the FAdE participates in the autoregulation of Ad4BP/SF-1 gene expression in the adrenal cortex at later stages of fetal development. However, given that the Ad4-1234-mut construct induced lacZ expression at E11.5, the Ad4 sites appear unnecessary for FAdE activity at earlier developmental stages. To confirm this hypothesis, we mated the SacK0.6 (line 9) Tg mouse (Fig. (Fig.2)2 Hox/Pbx1 and Pbx1/Prep1 binding sites in FAdE. The data presented above argue that Ad4BP/SF-1 maintains its own expression at later stages of development, but it remains unclear how Ad4BP/SF-1 expression is controlled prior to the maintenance phase of transcription. To address this question, we attempted to identify functional cis elements other than the Ad4 sites present in the FAdE. Because both Ad4 site 3 and site 4 are not required for lacZ expression and the 5′ region of the Ad4BP/SF-1 enhancer is not highly conserved, we generated a DNA fragment containing nucleotides 88 to 467 (Fig. (Fig.3A).3A When the sequence of this DNA fragment was examined in detail, we found potential binding sites for the Pbx/Prep and Pbx/Hox heterodimers present in the upstream region proximal to the Ad4 site 1 (Fig. (Fig.3A).3A
In order to identify Hox genes expressed in the adrenal primordium at stage E10.0, the primordial cells were collected from Tg fetuses carrying the hsp68 basal promoter with the FAdE. RNA prepared from these cells was subjected to RT-PCR with degenerate primers corresponding to a highly conserved homeodomain to amplify all Hox family members expressed. RNA prepared from E13.5 fetuses was also used for the analysis, and the amplified fragments were cloned and sequenced. Seventy and 95 clones for E10.0 and E13.5 fetuses, respectively, were analyzed, and the results were overlaid on a schematic map of the mouse Hox gene clusters (Fig. (Fig.5C).5C Binding of the Hox-Pbx-Prep complex to Pbx/Prep and Pbx/Hox sites in FAdE. EMSAs were performed to examine whether the Pbx/Prep and Pbx/Hox sites were recognized by in vitro-synthesized Pbx1, Prep1, and Hox proteins. When an oligonucleotide containing the Pbx/Prep site (Fig. (Fig.6A)6A
Prep1 can influence the Pbx-Hox complex through direct interactions with Pbx (3, 4). Indeed, Pbx/Prep sites are frequently localized near Pbx/Hox sites in some genes (13, 23, 48). Similar to these genes, FAdE contains both Pbx/Prep and Pbx/Hox sites with an 8-bp interval (Fig. (Fig.3A3A Function of Pbx/Prep and Pbx/Hox binding sites in vivo. We examined whether the binding sites contribute to the Ad4BP/SF-1-independent transcriptional activity of the FAdE. We used the short form of FAdE (88 to 476 bp) containing Ad4 sites 1 and 2 as well as the Pbx/Prep and Pbx/Hox binding sites for Tg assays (Fig. (Fig.7A).7A
DISCUSSION Fetal adrenal-specific enhancer of the Ad4BP/SF-1 gene. The Ad4BP/SF-1 gene is essential for the proper development and function of the adrenal cortex, gonads, pituitary gonadotrope, VMH, and spleen (38, 44, 57). Therefore, Ad4BP/SF-1 expression should be differentially regulated by tissue-specific enhancers and thus the identification of these tissue-specific enhancers seemed to provide insight into the regulation of tissue development. Toward this end, Tg mouse studies performed using BAC and YAC clones containing the Ad4BP/SF-1 gene locus successfully reproduced endogenous gene expression (24, 55). However, these studies did not identify any tissue-specific enhancers. An additional Tg mouse study used the proximal upstream region from −589 to +85 that was capable of driving transgene expression in the sexually indifferent fetal gonad (E11.5) and studies with cultured cells demonstrated that Wt1 and Lhx9 binding sites in this region are essential for Ad4BP/SF-1 gene transcription (59). However, whether this upstream region is sufficient to control gene expression at later developmental stages in the gonads or other target tissues remains unclear. Interestingly, Shima et al. recently identified a VMH-specific enhancer in intron 6 of the Ad4BP/SF-1 gene, strongly suggesting that other tissue-specific enhancers are localized in the locus (53). In the present study, we newly identified FAdE in intron 4 of the Ad4BP/SF-1 gene by using Tg mice assays. Similar to the VMH enhancer, the nucleotide sequence of the FAdE is conserved among animal species. However, this enhancer was unable to drive transgene expression in the adult adrenal cortex. Thus, the fetal and adult adrenal cortices appear to use different systems for the regulation of gene expression, and this may explain the distinct structures and functions observed between fetal and adult cortices. Interestingly, FAdE activity appears to be controlled by an autoregulatory loop through the interaction of Ad4BP/SF-1 with internal Ad4 sites in the FAdE. However, before autoregulation can begin, Ad4BP/SF-1 gene transcription must occur in an Ad4BP/SF-1-independent fashion. This hypothesis was clearly supported by the ability of Ad4 binding-deficient FAdE to drive transgene expression at E11.5, and moreover, the FAdE remained active in the adrenal primordium of Ad4BP/SF-1 knockout (KO) mice. After extensive investigation, we identified binding sites for Pbx-Hox and Pbx-Prep in FAdE and demonstrated that these sites are essential for the initial expression of Ad4BP/SF-1 prior to the establishment of autoregulation. The autoregulatory system likely maintains the intracellular concentration of Ad4BP/SF-1 at an appropriate level, and indeed the system is known to control the expression of transcription factors that are critically required for the development of certain tissues (14, 18, 61). Several lines of evidence suggest that Ad4BP/SF-1 gene dosage and subsequent protein expression levels are critical for target tissue development. Fetuses that are heterozygous for Ad4BP/SF-1 deficiency develop hypoplastic adrenal glands (7), and the same phenomenon is observed in the M33 KO mouse in which Ad4BP/SF-1 expression is downregulated to approximately half the level of the expression in wild-type mice (25). Interestingly, this defect is caused by decreased cell numbers of the adrenal primordia (7), suggesting that Ad4BP/SF-1 activates cell proliferation dose dependently. Thus, the expression levels of Ad4BP/SF-1 in the fetal adrenal gland appear to be fine tuned in a developmental stage- and tissue-specific manner by the function of the FAdE, although there are possible tissue differences in Ad4BP/SF-1 function. Correlation of fetal and X zones in the developing mouse adrenal cortex. The fetal adrenal cortices of many mammalian species consist of two distinct cell groups, small and tightly packed outer cells (adult zone) and larger and irregularly aligned inner cells (fetal zone) (27). During pregnancy, the adult zone remains undifferentiated, but the fetal zone enlarges and synthesizes steroids. After birth, the fetal zone regresses, while the adult zone increases in size. Although the rat and mouse fetal adrenal cortices develop two distinct layers like other mammalian species, their adrenal glands have been described as lacking a true fetal zone (30). In fact, the degeneration of the fetal zone and growth of the adult cortex starts in the late fetal stage in these rodents. In addition, the mouse adrenal cortex develops a unique islet of eosinophilic cells, the so-called X zone, after birth (21, 35). This particular layer disappears during puberty in male mice (21), whereas it persists for a longer period in females and undergoes regression during the first pregnancy (20). In this study, we examined lacZ reporter gene expression driven by the FAdE. LacZ expression was detected at E10.5 at the presumptive adrenal cortex. Thereafter, the expression was maintained until puberty in males but persisted until after sexual maturation in females. Interestingly, lacZ expression in females completely disappeared after the first pregnancy. This expression pattern is remarkably similar to the kinetics of X-zone regression, strongly suggesting that the lacZ-expressing cells comprise the X zone. However, lacZ-expressing cells were present during the fetal stage and the X zone has been thought to emerge after birth. This discrepancy may arise from the unique distribution of X-zone (lacZ-positive) cells at the postnatal stage. Shortly after birth, lacZ-positive cells are distributed sporadically in the medulla and thereafter they accumulate at the juxtamedullary region, where the X zone is thought to develop (17). Previous studies examining the X zone have relied on merely structural and histological observations, not marker gene expression, and this renders firm conclusions of the origins of the cells that comprise the X zone difficult. Therefore, it is reasonable to conclude that the fetal adrenal zone is present in the mouse fetus and is maintained after birth as X-zone cells. All of these data demonstrate that the developmental processes of the adrenal gland are extremely similar in mouse and other mammals. Role of Hox-Pbx1-Prep1 as upstream regulators of Ad4BP/SF-1. Hox transcription factors direct the patterning of various structures during the embryonic development of vertebrates and invertebrates through regulating numerous target genes (9, 33, 45). Based on the expression profile and binding specificity, Hoxb5, Hoxb9, Hoxc5, and possibly Hoxc6 were thought to regulate the Ad4BP/SF-1 expression in the fetal adrenal gland. The adrenal cortex is known to be derived from a certain part of the intermediate mesoderm lying along the anterior to posterior axis (16). To specify the adrenal region, these Hox gene products are thought to induce Ad4BP/SF-1 expression at this particular region of the mesoderm. As it has been established that Hox genes control anterior to posterior axial identity through regulating target gene expression, the location of the adrenal cortex could be determined by the combined expression of the particular set of the Hox genes. The binding and heterodimerization of Hox proteins with Pbx have been extensively investigated. The Pbx-Hox heterodimer binds a bipartite sequence comprised of two adjacent half sites in which Pbx contacts the 5′ half, while Hox contacts the more variable 3′ half (31). The Pbx/Hox site (CTGATAAATAA) found in the FAdE is highly similar to a consensus binding sequence for Pbx and certain Hox paralogue members (NTGATTNATNN) (10). In addition, the FAdE contains a Pbx/Prep (or Pbx/Meis) site near the Pbx/Hox site. The proximity of these two sites allows efficient formation of a ternary Hox-Pbx-Prep complex in vitro. Moreover, considering that a mutation at either of these two sites reduced the enhancer activity in vivo, both sites are crucial for complete functioning of the FAdE. Consistent with our current observations, the combined presence of these two binding sites in the regulatory regions of the Hoxb1, Hoxb2, and Phox2b was reported to direct cooperatively rhombomere-restricted expression (13, 23, 46, 50). Pbx1 appears to play critical roles during the early stages of adrenal development. Interestingly, mice deficient in the Pbx1 gene completely lack adrenal glands (51) as do Ad4BP/SF-1 gene-deficient mice. In the absence of Pbx1, Ad4BP/SF-1 expression is substantially reduced. Thus, considering the dose dependence of adrenal development on Ad4BP/SF-1 expression, it is likely that the low levels of Ad4BP/SF-1 in Pbx1-deficient mice are responsible for the defective adrenal development. Although the knockout study strongly suggested that Pbx1 regulates Ad4BP/SF-1 gene expression in the adrenal primordium, the molecular mechanism governing this regulation remained unclear. The present study greatly clarifies this mechanism and provides valuable insight into the overall mechanisms regulating cell fate determination in the fetal adrenal cortex. In summary, we have identified a fetal adrenal enhancer in the Ad4BP/SF-1 gene. An investigation of cis elements revealed that homeobox protein-containing complexes initially activate Ad4BP/SF-1 gene expression, which subsequently establishes an autoregulatory loop. These findings substantially provide a deeper understanding of adrenal development. Acknowledgments We thank K. Mihara and M. Sakaguchi (Kyushu University) for providing the anti-β-galactosidase antibody, Hideyuki Okano (Keio University) for providing nestinhsp68EGFP, Kazuhiko Umesono (Kyoto University) for pCMX, and Hiroe Kowa for technical assistance. This work was supported in part by Grants-in-Aid for Scientific Research and Grants-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Japan Science and Technology Corporation. REFERENCES 1. Abu-Shaar, M., H. D. Ryoo, and R. S. Mann. 1999. Control of the nuclear localization of extradenticle by competing nuclear import and export signals. Genes Dev. 13:935-945. [PubMed] 2. Achermann, J. C., M. Ito, P. C. Hindmarsh, and J. L. Jameson. 1999. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat. Genet. 22:125-126. [PubMed] 3. Berthelsen, J., V. Zappavigna, E. Ferretti, F. Mavilio, and F. Blasi. 1998. The novel homeoprotein Prep1 modulates Pbx-Hox protein cooperativity. EMBO J. 17:1434-1445. [PubMed] 4. Berthelsen, J., V. Zappavigna, F. Mavilio, and F. Blasi. 1998. Prep1, a novel functional partner of Pbx proteins. EMBO J. 17:1423-1433. [PubMed] 5. Biason-Lauber, A., and E. J. Schoenle. 2000. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. Am. J. Hum. Genet. 67:1563-1568. [PubMed] 6. Birk, O. S., D. E. Casiano, C. A. Wassif, T. Cogliati, L. Zhao, Y. Zhao, A. Grinberg, S. Huang, J. A. Kreidberg, K. L. Parker, F. D. Porter, and H. Westphal. 2000. The LIM homeobox gene Lhx9 is essential for mouse gonad formation. Nature 403:909-913. [PubMed] 7. Bland, M. L., R. C. Fowkes, and H. A. Ingraham. 2004. Differential requirement for steroidogenic factor-1 gene dosage in adrenal development versus endocrine function. Mol. Endocrinol. 18:941-952. [PubMed] 8. Burglin, T. R. 1997. Analysis of TALE superclass homeobox genes (MEIS, PBC, KNOX, Iroquois, TGIF) reveals a novel domain conserved between plants and animals. Nucleic Acids Res. 25:4173-4180. [PubMed] 9. Capecchi, M. R. 1997. Role of Hox genes and hindbrain development, p. 334-355. In W. M. Cowan, T. M. Jessell, and S. L. Zipursky (ed.), Molecular and cellular aspects of neural development. Oxford University Press, New York, N.Y. 10. Chang, C. P., L. Brocchieri, W. F. Shen, C. Largman, and M. L. Cleary. 1996. Pbx modulation of Hox homeodomain amino-terminal arms establishes different DNA-binding specificities across the Hox locus. Mol. Cell. Biol. 16:1734-1745. [PubMed] 11. Correa, R. V., S. Domenice, N. C. Bingham, A. E. Billerbeck, W. E. Rainey, K. L. Parker, and B. B. Mendonca. 2004. A microdeletion in the ligand binding domain of human steroidogenic factor 1 causes XY sex reversal without adrenal insufficiency. J. Clin. Endocrinol. Metab. 89:1767-1772. [PubMed] 12. Cui, S., A. Ross, N. Stallings, K. L. Parker, B. Capel, and S. E. Quaggin. 2004. Disrupted gonadogenesis and male-to-female sex reversal in Pod1 knockout mice. Development 131:4095-4105. [PubMed] 13. Ferretti, E., H. Marshall, H. Popperl, M. Maconochie, R. Krumlauf, and F. Blasi. 2000. Segmental expression of Hoxb2 in r4 requires two separate sites that integrate cooperative interactions between Prep1, Pbx and Hox proteins. Development 127:155-166. [PubMed] 14. Ghislain, J., C. Desmarquet-Trin-Dinh, P. Gilardi-Hebenstreit, P. Charnay, and M. Frain. 2003. Neural crest patterning: autoregulatory and crest-specific elements co-operate for Krox20 transcriptional control. Development 130:941-953. [PubMed] 15. Hasegawa, T., M. Fukami, N. Sato, N. Katsumata, G. Sasaki, K. Fukutani, K. Morohashi, and T. Ogata. 2004. Testicular dysgenesis without adrenal insufficiency in a 46, XY patient with a heterozygous inactive mutation of steroidogenic factor-1. J. Clin. Endocrinol. Metab. 89:5930-5935. [PubMed] 16. Hatano, O., A. Takakusu, M. Nomura, and K. Morohashi. 1996. Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF-1. Genes Cells 1:663-671. [PubMed] 17. Hirokawa, N., and H. Ishikawa. 1974. Electron microscopic observations on postnatal development of the X zone in mouse adrenal cortex. Z. Anat. Entwicklungsgesch. 144:85-100. [PubMed] 18. Hiromi, Y., and W. J. Gehring. 1987. Regulation and function of the Drosophila segmentation gene fushi tarazu. Cell 50:963-974. [PubMed] 19. Hogan, B., R. Beddington, F. Constantini, and E. Lacy. 1994. Manipulating the mouse embryo: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 20. Holmes, P. V., and A. D. Dickson. 1971. X-zone degeneration in the adrenal glands of adult and immature female mice. J. Anat. 108:159-168. [PubMed] 21. Howard-Miller, E. 1927. A transitory zone in the adrenal cortex which shows age and sex relationships. Am. J. Anat. 40:251-293. 22. Ingraham, H. A., D. S. Lala, Y. Ikeda, X. Luo, W. H. Shen, M. W. Nachtigal, R. Abbud, J. H. Nilson, and K. L. Parker. 1994. The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis. Genes Dev. 8:2302-2312. [PubMed] 23. Jacobs, Y., C. A. Schnabel, and M. L. Cleary. 1999. Trimeric association of Hox and TALE homeodomain proteins mediates Hoxb2 hindbrain enhancer activity. Mol. Cell. Biol. 19:5134-5142. [PubMed] 24. Karpova, T., J. Presley, R. R. Manimaran, S. P. Scherrer, L. Tejada, K. R. Peterson, and L. L. Heckert. 2005. A FTZ-F1-containing yeast artificial chromosome recapitulates expression of steroidogenic factor 1 in vivo. Mol. Endocrinol. 19:2549-2563. [PubMed] 25. Katoh-Fukui, Y., A. Owaki, Y. Toyama, M. Kusaka, Y. Shinohara, M. Maekawa, K. Toshimori, and K. Morohashi. 2005. Mouse Polycomb M33 is required for splenic vascular and adrenal gland formation through regulating Ad4BP/SF1 expression. Blood 106:1612-1620. [PubMed] 26. Kawaguchi, A., T. Miyata, K. Sawamoto, N. Takashita, A. Murayama, W. Akamatsu, M. Ogawa, M. Okabe, Y. Tano, S. A. Goldman, and H. Okano. 2001. Nestin-EGFP transgenic mice: visualization of the self-renewal and multipotency of CNS stem cells. Mol. Cell. Neurosci. 17:259-273. [PubMed] 27. Keegan, C. E., and G. D. Hammer. 2002. Recent insights into organogenesis of the adrenal cortex. Trends Endocrinol. Metab. 13:200-208. [PubMed] 28. Kimura, R., H. Yoshii, M. Nomura, N. Kotomura, T. Mukai, S. Ishihara, K. Ohba, T. Yanase, O. Gotoh, H. Nawata, and K. Morohashi. 2000. Identification of novel first exons in Ad4BP/SF-1 (NR5A1) gene and their tissue- and species-specific usage. Biochem. Biophys. Res. Commun. 278:63-71. [PubMed] 29. Kothary, R., S. Clapoff, S. Darling, M. D. Perry, L. A. Moran, and J. Rossant. 1989. Inducible expression of an hsp68-lacZ hybrid gene in transgenic mice. Development 105:707-714. [PubMed] 30. Lanman, J. T. 1953. The fetal zone of the adrenal gland: its developmental course, comparative anatomy, and possible physiologic functions. Medicine (Baltimore) 32:389-430. [PubMed] 31. LeBrun, D. P., and M. L. Cleary. 1994. Fusion with E2A alters the transcriptional properties of the homeodomain protein PBX1 in t(1;19) leukemias. Oncogene 9:1641-1647. [PubMed] 32. Luo, X., Y. Ikeda, and K. L. Parker. 1994. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 77:481-490. [PubMed] 33. Maconochie, M., S. Nonchev, A. Morrison, and R. Krumlauf. 1996. Paralogous Hox genes: function and regulation. Annu. Rev. Genet. 30:529-556. [PubMed] 34. Mann, R. S., and M. Abu-Shaar. 1996. Nuclear import of the homeodomain protein extradenticle in response to Wg and Dpp signalling. Nature 383:630-633. [PubMed] 35. Masui, K., and Y. Tamura. 1926. The effect of gonadectomy on the structure of the suprarenal gland of mice, with reference to the functional relation between this gland and the sex gland of the female. J. Coll. Tokyo Imp. Univ. 7:353-376. 36. Morohashi, K., S. Honda, Y. Inomata, H. Handa, and T. Omura. 1992. A common trans-acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s. J. Biol. Chem. 267:17913-17919. [PubMed] 37. Morohashi, K., H. Iida, M. Nomura, O. Hatano, S. Honda, T. Tsukiyama, O. Niwa, T. Hara, A. Takakusu, Y. Shibata, et al. 1994. Functional difference between Ad4BP and ELP, and their distributions in steroidogenic tissues. Mol. Endocrinol 8:643-653. [PubMed] 38. Morohashi, K., H. Tsuboi-Asai, S. Matsushita, M. Suda, M. Nakashima, H. Sasano, Y. Hataba, C. L. Li, J. Fukata, J. Irie, T. Watanabe, H. Nagura, and E. Li. 1999. Structural and functional abnormalities in the spleen of an mFtz-F1 gene-disrupted mouse. Blood 93:1586-1594. [PubMed] 39. Morohashi, K. I., and T. Omura. 1996. Ad4BP/SF-1, a transcription factor essential for the transcription of steroidogenic cytochrome P450 genes and for the establishment of the reproductive function. FASEB J. 10:1569-1577. [PubMed] 40. Nogami, M., A. Kohda, H. Taguchi, M. Nakao, T. Ikemura, and K. Okumura. 2000. Relative locations of the centromere and imprinted SNRPN gene within chromosome 15 territories during the cell cycle in HL60 cells. J. Cell Sci. 113:2157-2165. [PubMed] 41. Nomura, M., S. Bartsch, H. Nawata, T. Omura, and K. Morohashi. 1995. An E box element is required for the expression of the ad4bp gene, a mammalian homologue of ftz-f1 gene, which is essential for adrenal and gonadal development. J. Biol. Chem. 270:7453-7461. [PubMed] 42. Nuclear Receptors Nomenclature Committee. 1999. A unified nomenclature system for the nuclear receptor superfamily. Cell 97:161-163. [PubMed] 43. Park, S. Y., J. J. Meeks, G. Raverot, L. E. Pfaff, J. Weiss, G. D. Hammer, and J. L. Jameson. 2005. Nuclear receptors Sf1 and Dax1 function cooperatively to mediate somatic cell differentiation during testis development. Development 132:2415-2423. [PubMed] 44. Parker, K. L., D. A. Rice, D. S. Lala, Y. Ikeda, X. Luo, M. Wong, M. Bakke, L. Zhao, C. Frigeri, N. A. Hanley, N. Stallings, and B. P. Schimmer. 2002. Steroidogenic factor 1: an essential mediator of endocrine development. Recent Prog. Horm. Res. 57:19-36. [PubMed] 45. Pearson, J. C., D. Lemons, and W. McGinnis. 2005. Modulating Hox gene functions during animal body patterning. Nat. Rev. Genet. 6:893-904. [PubMed] 46. Popperl, H., M. Bienz, M. Studer, S. K. Chan, S. Aparicio, S. Brenner, R. S. Mann, and R. Krumlauf. 1995. Segmental expression of Hoxb-1 is controlled by a highly conserved autoregulatory loop dependent upon exd/pbx. Cell 81:1031-1042. [PubMed] 47. Rieckhof, G. E., F. Casares, H. D. Ryoo, M. Abu-Shaar, and R. S. Mann. 1997. Nuclear translocation of extradenticle requires homothorax, which encodes an extradenticle-related homeodomain protein. Cell 91:171-183. [PubMed] 48. Ryoo, H. D., T. Marty, F. Casares, M. Affolter, and R. S. Mann. 1999. Regulation of Hox target genes by a DNA bound homothorax/Hox/extradenticle complex. Development 126:5137-5148. [PubMed] 49. Sadovsky, Y., P. A. Crawford, K. G. Woodson, J. A. Polish, M. A. Clements, L. M. Tourtellotte, K. Simburger, and J. Milbrandt. 1995. Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side-chain-cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids. Proc. Natl. Acad. Sci. USA 92:10939-10943. [PubMed] 50. Samad, O. A., M. J. Geisen, G. Caronia, I. Varlet, V. Zappavigna, J. Ericson, C. Goridis, and F. M. Rijli. 2004. Integration of anteroposterior and dorsoventral regulation of Phox2b transcription in cranial motoneuron progenitors by homeodomain proteins. Development 131:4071-4083. [PubMed] 51. Schnabel, C. A., L. Selleri, and M. L. Cleary. 2003. Pbx1 is essential for adrenal development and urogenital differentiation. Genesis 37:123-130. [PubMed] 52. Shen, J. H., and H. A. Ingraham. 2002. Regulation of the orphan nuclear receptor steroidogenic factor 1 by Sox proteins. Mol. Endocrinol. 16:529-540. [PubMed] 53. Shima, Y., M. Zubair, S. Ishihara, Y. Shinohara, S. Oka, S. Kimura, S. Okamoto, Y. Minokoshi, S. Suita, and K. Morohashi. 2005. Ventromedial hypothalamic nucleus-specific enhancer of Ad4BP/SF-1 gene. Mol. Endocrinol. 19:2812-2823. [PubMed] 54. Shinoda, K., H. Lei, H. Yoshii, M. Nomura, M. Nagano, H. Shiba, H. Sasaki, Y. Osawa, Y. Ninomiya, O. Niwa, et al. 1995. Developmental defects of the ventromedial hypothalamic nucleus and pituitary gonadotroph in the Ftz-F1 disrupted mice. Dev. Dyn. 204:22-29. [PubMed] 55. Stallings, N. R., N. A. Hanley, G. Majdic, L. Zhao, M. Bakke, and K. L. Parker. 2002. Development of a transgenic green fluorescent protein lineage marker for steroidogenic factor 1. Mol. Endocrinol. 16:2360-2370. [PubMed] 56. Tamura, M., Y. Kanno, S. Chuma, T. Saito, and N. Nakatsuji. 2001. Pod-1/capsulin shows a sex- and stage-dependent expression pattern in the mouse gonad development and represses expression of Ad4BP/SF-1. Mech. Dev. 102:135-144. [PubMed] 57. Val, P., A. M. Lefrancois-Martinez, G. Veyssiere, and A. Martinez. 2003. SF-1 a key player in the development and differentiation of steroidogenic tissues. Nucl. Recept. 1:8. [PubMed] 58. Wasserman, W. W., M. Palumbo, W. Thompson, J. W. Fickett, and C. E. Lawrence. 2000. Human-mouse genome comparisons to locate regulatory sites. Nat. Genet. 26:225-228. [PubMed] 59. Wilhelm, D., and C. Englert. 2002. The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1. Genes Dev. 16:1839-1851. [PubMed] 60. Yoshioka, H., Y. Ishimaru, N. Sugiyama, N. Tsunekawa, T. Noce, M. Kasahara, and K. Morohashi. 2005. Mesonephric FGF signaling is associated with the development of sexually indifferent gonadal primordium in chick embryos. Dev. Biol. 280:150-161. [PubMed] 61. Zhou, B., B. Wu, K. L. Tompkins, K. L. Boyer, J. C. Grindley, and H. S. Baldwin. 2005. Characterization of Nfatc1 regulation identifies an enhancer required for gene expression that is specific to pro-valve endocardial cells in the developing heart. Development 132:1137-1146. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Cell. 1999 Apr 16; 97(2):161-3.
[Cell. 1999]FASEB J. 1996 Dec; 10(14):1569-77.
[FASEB J. 1996]Recent Prog Horm Res. 2002; 57():19-36.
[Recent Prog Horm Res. 2002]Nucl Recept. 2003 Sep 18; 1(1):8.
[Nucl Recept. 2003]Cell. 1994 May 20; 77(4):481-90.
[Cell. 1994]J Biol Chem. 1995 Mar 31; 270(13):7453-61.
[J Biol Chem. 1995]Mech Dev. 2001 Apr; 102(1-2):135-44.
[Mech Dev. 2001]Development. 2004 Aug; 131(16):4095-105.
[Development. 2004]Genes Dev. 2002 Jul 15; 16(14):1839-51.
[Genes Dev. 2002]Mol Endocrinol. 2002 Mar; 16(3):529-40.
[Mol Endocrinol. 2002]Nucleic Acids Res. 1997 Nov 1; 25(21):4173-80.
[Nucleic Acids Res. 1997]Genes Dev. 1999 Apr 15; 13(8):935-45.
[Genes Dev. 1999]Nature. 1996 Oct 17; 383(6601):630-3.
[Nature. 1996]Nat Rev Genet. 2005 Dec; 6(12):893-904.
[Nat Rev Genet. 2005]Cell. 1997 Oct 17; 91(2):171-83.
[Cell. 1997]Trends Endocrinol Metab. 2002 Jul; 13(5):200-8.
[Trends Endocrinol Metab. 2002]Biochem Biophys Res Commun. 2000 Nov 11; 278(1):63-71.
[Biochem Biophys Res Commun. 2000]Development. 1989 Apr; 105(4):707-14.
[Development. 1989]Mol Cell Neurosci. 2001 Feb; 17(2):259-73.
[Mol Cell Neurosci. 2001]J Cell Sci. 2000 Jun; 113 ( Pt 12)():2157-65.
[J Cell Sci. 2000]Mol Endocrinol. 1994 May; 8(5):643-53.
[Mol Endocrinol. 1994]EMBO J. 1998 Mar 2; 17(5):1434-45.
[EMBO J. 1998]J Biol Chem. 1992 Sep 5; 267(25):17913-9.
[J Biol Chem. 1992]Biochem Biophys Res Commun. 2000 Nov 11; 278(1):63-71.
[Biochem Biophys Res Commun. 2000]Mol Endocrinol. 2005 Nov; 19(11):2812-23.
[Mol Endocrinol. 2005]Nat Genet. 2000 Oct; 26(2):225-8.
[Nat Genet. 2000]Development. 1989 Apr; 105(4):707-14.
[Development. 1989]Genes Cells. 1996 Jul; 1(7):663-71.
[Genes Cells. 1996]Dev Biol. 2005 Apr 1; 280(1):150-61.
[Dev Biol. 2005]J Biol Chem. 1992 Sep 5; 267(25):17913-9.
[J Biol Chem. 1992]Mol Endocrinol. 2004 Apr; 18(4):941-52.
[Mol Endocrinol. 2004]Cell. 1994 May 20; 77(4):481-90.
[Cell. 1994]EMBO J. 1998 Mar 2; 17(5):1434-45.
[EMBO J. 1998]EMBO J. 1998 Mar 2; 17(5):1423-33.
[EMBO J. 1998]Development. 2000 Jan; 127(1):155-66.
[Development. 2000]Mol Cell Biol. 1999 Jul; 19(7):5134-42.
[Mol Cell Biol. 1999]Development. 1999 Nov; 126(22):5137-48.
[Development. 1999]Blood. 1999 Mar 1; 93(5):1586-94.
[Blood. 1999]Recent Prog Horm Res. 2002; 57():19-36.
[Recent Prog Horm Res. 2002]Nucl Recept. 2003 Sep 18; 1(1):8.
[Nucl Recept. 2003]Mol Endocrinol. 2005 Oct; 19(10):2549-63.
[Mol Endocrinol. 2005]Mol Endocrinol. 2002 Oct; 16(10):2360-70.
[Mol Endocrinol. 2002]Development. 2003 Mar; 130(5):941-53.
[Development. 2003]Cell. 1987 Sep 11; 50(6):963-74.
[Cell. 1987]Development. 2005 Mar; 132(5):1137-46.
[Development. 2005]Mol Endocrinol. 2004 Apr; 18(4):941-52.
[Mol Endocrinol. 2004]Blood. 2005 Sep 1; 106(5):1612-20.
[Blood. 2005]Trends Endocrinol Metab. 2002 Jul; 13(5):200-8.
[Trends Endocrinol Metab. 2002]Medicine (Baltimore). 1953 Dec; 32(4):389-430.
[Medicine (Baltimore). 1953]J Anat. 1971 Jan; 108(Pt 1):159-68.
[J Anat. 1971]Z Anat Entwicklungsgesch. 1974 Jul 5; 144(1):85-100.
[Z Anat Entwicklungsgesch. 1974]Annu Rev Genet. 1996; 30():529-56.
[Annu Rev Genet. 1996]Nat Rev Genet. 2005 Dec; 6(12):893-904.
[Nat Rev Genet. 2005]Genes Cells. 1996 Jul; 1(7):663-71.
[Genes Cells. 1996]Oncogene. 1994 Jun; 9(6):1641-7.
[Oncogene. 1994]Mol Cell Biol. 1996 Apr; 16(4):1734-45.
[Mol Cell Biol. 1996]Development. 2000 Jan; 127(1):155-66.
[Development. 2000]Mol Cell Biol. 1999 Jul; 19(7):5134-42.
[Mol Cell Biol. 1999]Cell. 1995 Jun 30; 81(7):1031-42.
[Cell. 1995]Genesis. 2003 Nov; 37(3):123-30.
[Genesis. 2003]